GLA-SE adjuvant

Phase 2Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

GLA-SE adjuvant is one of 2 biologic programs targeting HIV Prevention. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV PreventionNot yet recruiting

HIV PreventionPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in HIV Prevention

#DrugCompanyPhaseTrials

GLA-SE adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 2

Alhydrogel Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

HIV Prevention

NCT07675629

Clinical

Trials by Indication[1]

Immunogenicity3 trials

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03220724·117 enrolled

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03409276·60 enrolled

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Completed·WWorcester HIV Vaccine·Phase 1·NCT04927585·42 enrolled

Immune Response1 trial

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed·HHIV Vaccine Trials Network·Phase 1·NCT04607408·38 enrolled

HIV Prevention1 trial

Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV

Not yet recruiting·WWorcester HIV Vaccine·Phase 2·NCT07675629·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GLA-SE adjuvant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLA-SE adjuvant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLA-SE adjuvant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

GLA-SE adjuvant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Immunogenicity3 trials

Immune Response1 trial

HIV Prevention1 trial

References

Drug Info

Quick Facts

Related News